About Us

The PAMPA trial team is based out of five medical centers in the United States and Canada. The lead investigators of the trial are Dr. Jose Scher of NYU and Dr. Christopher Ritchlin of University of Rochester. The five study sites include:

NYU Grossman School of Medicine, New York City, NY

Investigators: Dr. Jose Scher, Dr. Rebecca Haberman, Dr. Rebecca Blank, Dr. Jonathan Samuels, Dr. Michael Toprover

Brigham and Women’s Center, Boston, MA

Investigators: Dr. Joseph Merola

Women’s College Research Institute, Toronto, ON, Canada

Investigators: Dr. Lihi Eder, Dr. Vincent Piguet, Dr. Jensen Yeung

University of Rochester Medical Center, Rochester, NY

Investigators: Dr. Christopher Ritchlin, Dr. Ralf Thiele, Dr. Francisco Tausk

NewLab Clinical Research, St. John’s, NFLD, Canada

Investigators: Dr. Wayne Gulliver, Dr. Proton Rahman

About our Study

The PAMPA (Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort) Study is a multi-center, multi-year clinical trial that will study the extent to which we can slow or prevent the development of Psoriatic Arthritis (PsA) in patients with psoriasis.

Psoriatic arthritis is an inflammatory form of arthritis that attacks the joints and the surrounding tendons and ligaments. It causes pain and swelling in and around joints, which can lead to permanent damage and decreased quality of life. It most often affects those with a history of psoriasis of the skin. As many as 10 million Americans have psoriasis and approximately 30% of people with psoriasis ultimately develop PsA. Early recognition, diagnosis and treatment of PsA are extremely important and may help prevent or limit further joint damage, pain, and disability.

This study will help us determine whether we can use existing pharmaceuticals to prevent the development of PsA in people with psoriasis. If you are a candidate for this study and agree to voluntarily participate, you will take part in medical exams and surveys over the course of a two-year period and we may provide you with a study drug approved for the treatment of psoriasis.